Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

Novavax's partners Sanofi and Takeda have secured regulatory approvals for the XFG-adapted Nuvaxovid vaccine for the 2026-2027 season in the U.S., EU, and Japan. These clearances enable Novavax to earn royalties on net sales without maintaining its own commercial infrastructure, reinforcing its asset-light partnership strategy. Takeda has established Nuvaxovid as the second-leading COVID-19 vaccine in Japan, while Sanofi prepares for expanded marketing efforts in the U.S.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.